Age, Biography and Wiki

William Paul Duprex was born on 1968 in Lurgan, Northern Ireland. Discover William Paul Duprex's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 55 years old?

Popular As William Paul Duprex
Occupation Scientist
Age 55 years old
Zodiac Sign
Born 1968
Birthday 1968
Birthplace Lurgan, Northern Ireland
Nationality Ireland

We recommend you to check the complete list of Famous People born on 1968. He is a member of famous with the age 55 years old group.

William Paul Duprex Height, Weight & Measurements

At 55 years old, William Paul Duprex height not available right now. We will update William Paul Duprex's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

William Paul Duprex Net Worth

His net worth has been growing significantly in 2022-2023. So, how much is William Paul Duprex worth at the age of 55 years old? William Paul Duprex’s income source is mostly from being a successful . He is from Ireland. We have estimated William Paul Duprex's net worth , money, salary, income, and assets.

Net Worth in 2023 $1 Million - $5 Million
Salary in 2023 Under Review
Net Worth in 2022 Pending
Salary in 2022 Under Review
House Not Available
Cars Not Available
Source of Income

William Paul Duprex Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

2020

Since the start of the COVID-19 pandemic, Duprex has used his public profile on Twitter to share information about the virus and promote vaccination, which he had been outspoken about prior to the pandemic. Since COVID-19 emerged, Duprex has appeared as a subject matter expert in television, radio, and print news outlets. Duprex's team began working with live SARS-CoV-2 virus in February 2020, immediately helping to validate a PCR-based COVID-19 test developed by the University of Pittsburgh Medical Center (UPMC). In April 2020, Duprex secured one of the first Coalition for Epidemic Preparedness Innovation (CEPI) grants funding the creation of a COVID-19 vaccine, together with partners at the Pasteur Institute in Paris and Themis Bioscience in Austria. This particular vaccine was designed to use a recombinant measles vaccine as a vector for introducing SARS-CoV-2 spike protein into the body. Merck acquired Themis in June 2020 and abandoned all COVID-19 vaccine research in January 2021. Since then, Duprex's team has been focused on understanding how the SARS-CoV-2 virus mutates to create new viral variants, including Delta and Omicron, which the World Health Organization declared variants of concern. With collaborators at Carnegie Mellon University, he is working on improving vaccine delivery systems that can more safely and effectively reach remote parts of the developing world.

2006

From 2006 to 2007, Duprex worked at Johnson & Johnson as a Principal Scientist and Head of the Department of Emerging Sciences and Technologies, working to create heat-stable vaccines that are more suitable for distributing throughout the developing world. Duprex moved to Boston University in 2010 to take the positions of associate professor of Microbiology and Director of Cell and Tissue Imaging in the National Emerging Infectious Diseases Laboratories, where he trained to use "space-suit-virology" in a BSL-4 lab to understand pathogenesis in paramyxoviruses such as measles, mumps, and respiratory syncytial virus in humans, as well as Hendra virus in horses and Newcastle disease virus in chickens. During this time, he won funding from the Bill & Melinda Gates Foundation Grand Challenges in Global Health to continue his work with heat-stable measles vaccines. In 2018, Duprex became director of the Center for Vaccine Research at the University of Pittsburgh, where he continues to study the evolution of human and animal respiratory viruses such as measles, mumps and SARS-CoV-2, with the practical goals of developing new vaccines for emerging diseases as well as tools that predict viral spillover from animal reservoirs into humans.

1995

Duprex stayed on at QUB as a postdoctoral research fellow from 1995 to 1999, studying how measles virus infects the brain, and served as a lecturer in molecular virology and biochemistry from 1999 to 2010, during which time he studied measles, mumps, canine distemper, and foot-and-mouth disease virus in biocontainment at the Pirbright Institute.

1990

Duprex, who goes by his middle name, Paul, was born to a Protestant family in Lurgan, Northern Ireland, during the violent political conflict known as The Troubles. He attended King's Park Primary School, Lurgan College, and Queen's University Belfast (QUB), where he earned a BS in biochemistry and genetics in 1990 and a PhD in molecular virology in 1995.

1968

William Paul Duprex (pronounced /djuːˈpreɪ/ dew-PRAY; born 1968) is a British scientist and advocate for vaccines and global health. He serves as Director of the University of Pittsburgh's Center for Vaccine Research and Regional Biocontainment Laboratory. Duprex holds the Jonas Salk Chair in Vaccine Research. He is also a professor of microbiology and molecular genetics at the University of Pittsburgh School of Medicine and serves as Editor-in-Chief of the Journal of General Virology, which is published by the Microbiology Society, and a senior editor of mSphere, published by the American Society for Microbiology. Duprex is an expert in measles and mumps viruses and studies viral spillover from animals to humans, including the SARS-CoV-2 virus that caused the COVID-19 pandemic. Duprex is a Fellow of the American Academy of Microbiology.